Dr. Howard explains that asparaginase is a unique and critical chemotherapy drug because it works by starving cancer cells of asparagine, an amino acid they need to survive. This mechanism is different from other cytotoxic drugs, making it an essential component of a successful treatment plan. He emphasizes that removing asparaginase from the treatment regimen can lead to a significant 20% increase in relapse rates, highlighting its indispensable role in improving patient outcomes.
Managing Asparaginase Toxicities
While asparaginase is highly effective, it has a long list of potential toxicities due to its impact on protein synthesis in the body. Dr. Howard details some of the most common and feared side effects:
- Diabetes: Caused by a lack of insulin, which is a protein.
- Thrombosis (blood clots): Due to a deficiency in antithrombin, another protein.
- Pancreatitis: A serious complication that was a major focus of the conference.
He stresses the importance of recognizing the early warning signs for each toxicity, such as frequent urination for high blood sugar, abdominal pain for pancreatitis, and seizures for cerebral thrombosis.
The Future of Pediatric Oncology
Dr. Howard shared an optimistic view on the future of pediatric ALL treatment, calling its history โthe best story in cancer care ever.โ He notes that survival rates have increased dramatically:
- From 50% to 70% with the introduction of asparaginase in 1978.
- From 70% to 90% through the optimal use and sequencing of existing medications.
- From 90% to 97% with the recent approval of the new drug, blinatumomab.
